Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q2
Quarterly report
9 Nov 23
ARS
2022 FY
Annual report to shareholders
12 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
15 Mar 23
20-F
2021 FY
Annual report (foreign)
13 Apr 22
20-F
2020 FY
Annual report (foreign)
29 Mar 21
20-F/A
2019 FY
Annual report (foreign) (amended)
4 Aug 20
20-F
2019 FY
Annual report (foreign)
3 Apr 20
Current reports
8-K
Submission of Matters to a Vote of Security Holders
9 Apr 24
8-K
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13 Mar 24
8-K
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
8 Mar 24
8-K
Other Events
6 Mar 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
18 Dec 23
8-K
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
9 Nov 23
8-K
Material Modifications to Rights of Security Holders
6 Nov 23
8-K
Departure of Directors or Certain Officers
1 Nov 23
8-K
Entry into a Material Definitive Agreement
12 Sep 23
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
424B3
Prospectus supplement
8 Mar 24
424B3
Prospectus supplement
8 Mar 24
424B4
Prospectus supplement with pricing info
6 Mar 24
424B3
Prospectus supplement
4 Mar 24
S-1/A
IPO registration (amended)
13 Feb 24
S-1
IPO registration
12 Feb 24
424B3
Prospectus supplement
31 Jan 24
424B3
Prospectus supplement
18 Dec 23
424B3
Prospectus supplement
9 Nov 23
Other
EFFECT
Notice of effectiveness
4 Apr 24
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
UPLOAD
Letter from SEC
13 Feb 24
EFFECT
Notice of effectiveness
20 Mar 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
CORRESP
Correspondence with SEC
8 Feb 23
Ownership
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
MICHAEL T SEMBER
30 Oct 23
4
Gordon Dunn
30 Oct 23
4
Michael Myers
30 Oct 23
4
Anthony James Culverwell
30 Oct 23
4
Joseph Patrick Cooper
30 Oct 23
4
Natalie Ee Mun Leong
30 Oct 23
4
Denise P. Carter
30 Oct 23
4
DENNIS LANGER
30 Oct 23
3
MICHAEL T SEMBER
7 Mar 23